Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neovascular Age-related Macular Degeneration (nAMD)
100%
Ranibizumab
100%
Neovascular AMD
100%
Fibrous Tissue
38%
Subfoveal
38%
Denmark
15%
Dosing Regimen
15%
Atrophy
15%
Visual Acuity
15%
Natural Course
15%
Pathological Changes
15%
VEGF Inhibitors
15%
Hazard Ratio
7%
Treatment Regimen
7%
Disease Course
7%
Inflammatory Response
7%
Clinical Characteristics
7%
Disease Activity
7%
Incidence Rate
7%
Randomized Clinical Trial
7%
Europe
7%
First Year
7%
Visual Outcome
7%
Retinal pigment Epithelium
7%
Age-related Changes
7%
Fibrosis
7%
Growth Pattern
7%
Oxidative Stress
7%
Blind People
7%
Annual Incidence
7%
Treatment Methods
7%
Intravitreal
7%
Visual Performance
7%
Subretinal Space
7%
Retinal Atrophy
7%
PhD Studies
7%
US Health Care
7%
Care Plan
7%
Monthly Dosing
7%
Visual Prognosis
7%
Ranibizumab Injection
7%
Pro Re Nata
7%
Legally Blind
7%
Photoreceptor Cells
7%
Visual Disability
7%
Choroidea
7%
Anti-VEGF Therapy
7%
Ranibizumab Treatment
7%
Medicine and Dentistry
Ranibizumab
100%
Wet Macular Degeneration
100%
Doctor of Philosophy
44%
Visual Acuity
22%
Vasculotropin Inhibitor
22%
Disease
11%
Epithelial Cell
11%
Disease Activity
11%
Serositis
11%
Randomized Clinical Trial
11%
Hazard Ratio
11%
Injury
11%
Optical Coherence Tomography
11%
Vision
11%
Vasculotropin
11%
Fibrosis
11%
Oxidative Stress
11%
Photoreceptor Cell
11%
Visual Pigment
11%
Pharmacology, Toxicology and Pharmaceutical Science
Wet Macular Degeneration
100%
Ranibizumab
100%
Vasculotropin Inhibitor
22%
Inflammation
11%
Disease Activity
11%
Disease
11%
Injury
11%
Randomized Clinical Trial
11%
Vasculotropin
11%
Visual Pigment
11%
Fibrosis
11%